← Back to Search

Virus Therapy

Booster Dose of BNT162b2 Vaccine for Cancer

Phase 2

Recruiting

Research Sponsored by Montefiore Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 weeks after booster dose

Awards & highlights

Study Summary

This trial will test if a booster shot of the COVID vaccine is safe and effective in cancer patients who didn't develop antibodies from the original vaccine series.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 weeks after booster dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 weeks after booster dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks after booster dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rates of seroconversion for SARS-CoV-2 spike antibody

Trial Design

1Treatment groups

Experimental Treatment

Group I: Booster doseExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Montefiore Medical CenterLead Sponsor

441 Previous Clinical Trials

581,946 Total Patients Enrolled

Albert Einstein College of MedicineOTHER

287 Previous Clinical Trials

11,856,857 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the BNT162b2 vaccine been officially sanctioned by the FDA?

"BNT162b2 vaccine has been assessed to be a 2 on the rating scale. This is because, while there are some safety data available from Phase 2 trials, efficacy data remain unavailable at this time."

Answered by AI

Does this particular experiment offer a pioneering approach?

"Currently, 27 clinical trials testing BNT162b2 vaccine are occurring in 220 cities across 27 nations. This journey began with BioNTech SE's Phase 1 & 2 trial which included 512 participants and was completed in 2020. Since then, 16 investigations into the drug have been finished successfully."

Answered by AI

What other research has been undertaken with regard to the BNT162b2 immunization?

"Presently, there are 27 ongoing investigations into the efficacy of BNT162b2 vaccine with 6 in Phase 3. Primarily based in Roskilde and Aarhus N, these studies have expanded to 762 locations worldwide."

Answered by AI

Are applicants currently being accepted for this investigation?

"Updated information on clinicaltrials.gov confirms that this research study is enrolling patients now. This trial was first introduced to the public on August 10th 2021, and subsequently revised October 12th 2022."

Answered by AI

What is the highest patient capacity for this experiment?

"Indeed, the clinicaltrials.gov listing confirms that this trial is presently onboarding patients. This research study was first made available on August 10th 2021 and has since been refreshed on October 12th 2022. The investigators are seeking out 100 individuals at a single site to complete the experiment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Booster Dose Trial

Balazs Halmos 2021. "Booster Dose Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05016622.